Aegis Therapeutics and Dr Reddy's in strategic alliance for Intravail

Dr Reddy's Laboratories, India's second-largest drugmaker, and San Diego, USA-based Aegis Therapeutics have entered into a partnership providing Dr Reddy's with access to Aegis' Intravail drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of $1 billion. Financial terms of the deal were not disclosed.

Commenting on the collaboration, Raghav Chari, senior vice president - Proprietary Products business, at the Indian firm, said, "We are extremely pleased to be working with Aegis and gaining access to their patented Intravail drug delivery technologies. The results of successful human studies completed to date will provide a unique product offering, satisfying a significant unmet need in the market. We hope this will continue to provide affordable and innovative medicines to a much wider population."

The products under the exclusive license agreement will be developed, manufactured and marketed worldwide by Dr Reddy's.